{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:14:44Z","timestamp":1791173684286,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.yexcr.2014.01.026","type":"journal-article","created":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T11:45:37Z","timestamp":1391255137000},"page":"50-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Antisense-mediated exon skipping: Taking advantage of a trick from Mother Nature to treat rare genetic diseases"],"prefix":"10.1016","volume":"325","author":[{"given":"Marcel","family":"Veltrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2014.01.026_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1749-6632.2010.05836.x","article-title":"New insights in gene-derived therapy: the example of Duchenne muscular dystrophy","volume":"1214","author":"Aartsma-Rus","year":"2010","journal-title":"Ann. N. Y. Acad. Sci"},{"key":"10.1016\/j.yexcr.2014.01.026_bib2","first-page":"257","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"3","author":"Aartsma-Rus","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.yexcr.2014.01.026_bib3","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1073\/pnas.0604893104","article-title":"Lack of myostatin results in excessive muscle growth but impaired force generation","volume":"104","author":"Amthor","year":"2007","journal-title":"Proc. Nat. Acad. Sci. U.S.A"},{"key":"10.1016\/j.yexcr.2014.01.026_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/402369","article-title":"Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy","author":"Aoki","year":"2013","journal-title":"Biomed. Res. Int"},{"key":"10.1016\/j.yexcr.2014.01.026_bib5","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/mtna.2012.30","article-title":"Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.yexcr.2014.01.026_bib6","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/hmg\/ddl107","article-title":"In-frame deletion in a novel centrosomal\/ciliary protein CEP290\/NPHP6 perturbs its interaction with RPGR and results in early-onset retinal degeneration in the rd16 mouse","volume":"15","author":"Chang","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.yexcr.2014.01.026_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.yexcr.2014.01.026_bib8","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1038\/mtna.2012.3","article-title":"Antisense oligonucleotide (AON)-based therapy for Leber congenital amaurosis caused by a frequent mutation in CEP290","volume":"1","author":"Collin","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.yexcr.2014.01.026_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D\u2019Amico","year":"2011","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.yexcr.2014.01.026_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.mcn.2013.04.005","article-title":"Splicing therapy for neuromuscular disease","volume":"56","author":"Douglas","year":"2013","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.yexcr.2014.01.026_bib11","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1172\/JCI69448","article-title":"Disruption of CEP290 microtubule\/membrane-binding domains causes retinal degeneration","volume":"123","author":"Drivas","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yexcr.2014.01.026_bib12","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1038\/mtna.2012.21","article-title":"AON-mediated exon skipping restores ciliation in fibroblasts harboring the common Leber congenital amaurosis CEP290 mutation","volume":"1","author":"Gerard","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.yexcr.2014.01.026_bib13","doi-asserted-by":"crossref","first-page":"E33","DOI":"10.1152\/ajpendo.00651.2012","article-title":"Lack of myostatin impairs mechanical performance and ATP cost of contraction in exercising mouse gastrocnemius muscle in vivo","volume":"305","author":"Giannesini","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.yexcr.2014.01.026_bib14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne\u2019s muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2014.01.026_bib15","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1126\/science.1104297","article-title":"Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping","volume":"306","author":"Goyenvalle","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.yexcr.2014.01.026_bib16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2202-14-148","article-title":"Lack of exon 10 in the murine tau gene results in mild sensorimotor defects with aging","volume":"14","author":"Gumucio","year":"2013","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.yexcr.2014.01.026_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/wrna.1158","article-title":"Targeting RNA splicing for disease therapy","volume":"4","author":"Havens","year":"2013","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"10.1016\/j.yexcr.2014.01.026_bib18","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/mt.2010.72","article-title":"Preclinical PK and PD studies on 2\u2032-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model","volume":"18","author":"Heemskerk","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yexcr.2014.01.026_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2014.01.026_bib20","article-title":"A chemical view of oligonucleotides for exon skipping and related drug applications","author":"Jarver","year":"2013","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.yexcr.2014.01.026_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/mt.2010.212","article-title":"Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment","volume":"19","author":"Kang","year":"2011","journal-title":"Mol. Ther"},{"key":"10.1016\/j.yexcr.2014.01.026_bib22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1242\/dmm.010280","article-title":"Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis","volume":"5","author":"Kaplan","year":"2012","journal-title":"Dis. Model. Mech"},{"key":"10.1016\/j.yexcr.2014.01.026_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1755-8794-4-36","article-title":"Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy","volume":"4","author":"Kemaladewi","year":"2011","journal-title":"BMC Med. Genomics"},{"key":"10.1016\/j.yexcr.2014.01.026_bib24","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.yexcr.2014.01.026_bib25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/hum.2012.234","article-title":"Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy","volume":"24","author":"Koo","year":"2013","journal-title":"Hum. Gene Ther"},{"key":"10.1016\/j.yexcr.2014.01.026_bib26","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm897","article-title":"Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse","volume":"9","author":"Lu","year":"2003","journal-title":"Nat. Med"},{"key":"10.1016\/j.yexcr.2014.01.026_bib27","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1038\/mtna.2012.54","article-title":"Dual myostatin and dystrophin exon skipping by morpholino nucleic acid oligomers conjugated to a cell-penetrating peptide is a promising therapeutic strategy for the treatment of Duchenne muscular dystrophy","volume":"1","author":"Malerba","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.yexcr.2014.01.026_bib28","doi-asserted-by":"crossref","unstructured":"R. Mendell, L.R. Rodino-Klapac, Z. Sahenk, K. Roush, L. Bird, L.P. Lowes, L. Alfano, A.M. Gomez, S. Lewis, J. Kota, V. Malik, K. Shontz, C.M. Walker, K.M. Flanigan, M. Corridore, J.R. Kean, H.D. Allen, C. Shilling, K.R. Melia, P. Sazani, J.B. Saoud, E.M. Kaye, Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol.2013).","DOI":"10.1002\/ana.23982"},{"key":"10.1016\/j.yexcr.2014.01.026_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5435\/JAAOS-20-06-393","article-title":"Spinal muscular atrophy: manifestations and management","volume":"20","author":"Mesfin","year":"2012","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"10.1016\/j.yexcr.2014.01.026_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1266\/ggs.87.213","article-title":"Genetic abnormalities in fibrodysplasia ossificans progressiva","volume":"87","author":"Miao","year":"2012","journal-title":"Genes Genet. Syst."},{"key":"10.1016\/j.yexcr.2014.01.026_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.yexcr.2014.01.026_bib32","doi-asserted-by":"crossref","first-page":"e62114","DOI":"10.1371\/journal.pone.0062114","article-title":"Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy","volume":"8","author":"Mitrpant","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2014.01.026_bib33","doi-asserted-by":"crossref","first-page":"906943","DOI":"10.1155\/2011\/906943","article-title":"The domestic cat as a large animal model for characterization of disease and therapeutic intervention in hereditary retinal blindness","volume":"2011","author":"Narfstrom","year":"2011","journal-title":"J. Ophthalmol"},{"key":"10.1016\/j.yexcr.2014.01.026_bib34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1042\/BST20120091","article-title":"Tau alternative splicing in familial and sporadic tauopathies","volume":"40","author":"Niblock","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.yexcr.2014.01.026_bib35","doi-asserted-by":"crossref","first-page":"9836","DOI":"10.1093\/nar\/gks710","article-title":"Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing","volume":"40","author":"Peacey","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.yexcr.2014.01.026_bib36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/hum.2012.225","article-title":"Antisense oligonucleotides for the treatment of spinal muscular atrophy","volume":"24","author":"Porensky","year":"2013","journal-title":"Hum. Gene Ther"},{"key":"10.1016\/j.yexcr.2014.01.026_bib37","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1089\/hum.2013.052","article-title":"Exon skipping as a therapeutic strategy applied to an RYR1 mutation with pseudo-exon inclusion causing a severe core myopathy","volume":"24","author":"Rendu","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.yexcr.2014.01.026_bib38","doi-asserted-by":"crossref","first-page":"e69096","DOI":"10.1371\/journal.pone.0069096","article-title":"Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva","volume":"8","author":"Shi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2014.01.026_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/adna.18739","article-title":"Peptide nucleic acid (PNA) cell penetrating peptide (CPP) conjugates as carriers for cellular delivery of antisense oligomers","volume":"2","author":"Shiraishi","year":"2011","journal-title":"Artif. DNA PNA XNA"},{"key":"10.1016\/j.yexcr.2014.01.026_bib40","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.cell.2012.02.014","article-title":"Splice modulating therapies for human disease","volume":"148","author":"Spitali","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.yexcr.2014.01.026_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ajpath.2013.03.015","article-title":"Neurodegenerative disorder FTDP-17-related tau intron 10+16C\u2192T mutation increases tau exon 10 splicing and causes tauopathy in transgenic mice","volume":"183","author":"Umeda","year":"2013","journal-title":"Am. J. Pathol"},{"key":"10.1016\/j.yexcr.2014.01.026_bib42","article-title":"Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy","author":"van den Bergen","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.yexcr.2014.01.026_bib43","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa073108","article-title":"Local dystrophin restoration with antisense oligonucleotide PRO051","volume":"357","author":"van Deutekom","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2014.01.026_bib44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/pro.2266","article-title":"Structural analyses of the pre-mRNA splicing machinery","volume":"22","author":"Zhang","year":"2013","journal-title":"Protein Sci"},{"key":"10.1016\/j.yexcr.2014.01.026_bib45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/hum.2012.211","article-title":"A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice","volume":"24","author":"Zhou","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.yexcr.2014.01.026_bib46","doi-asserted-by":"crossref","unstructured":"H.L. Zhou, G. Luo, J.A. Wise, H. Lou, Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanisms. Nucleic Acids Res.2013).","DOI":"10.1093\/nar\/gkt875"}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482714000469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482714000469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T02:47:32Z","timestamp":1565146052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482714000469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0014482714000469"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2014.01.026","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense-mediated exon skipping: Taking advantage of a trick from Mother Nature to treat rare genetic diseases","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2014.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}